# Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (R01 Clinical Trial Not Allowed)

Source: https://welltoldgrants.com/grants/rfa-ai-24-010-feasibility-of-novel-diagnostics-for-tb-in-endemic/  
Official notice: https://www.grants.gov/search-results-detail/353243

> National Institutes of Health offered grants of up to $3.5 million to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on June 28, 2024.

| Field | Value |
|---|---|
| Opportunity number | RFA-AI-24-010 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | June 28, 2024 |
| Award ceiling | $3.5 million |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.855 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

## What the grant funds

The purpose of this notice of funding opportunity (NOFO) is to support the evaluation of early-stage diagnostics and novel diagnostic strategies for Tuberculosis (TB) in the context of existing clinical algorithms in TB endemic countries. Evaluation studies should: 1) perform proof-of principle studies of novel diagnostic tests and strategies for TB, including among people living with HIV (PLWH) and 2) provide feedback to diagnostic developers and policy makers on the performance of the technologies and most effective strategies for use of the diagnostic technologies in an endemic setting.

## Questions people ask

### Is RFA-AI-24-010 still open?

No. It closed on June 28, 2024.

### Who can apply for Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (R01 Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (R01 Clinical Trial Not Allowed)?

Closed June 28, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $3.5 million each.

### Who has been funded under RFA-AI-24-010?

NIH RePORTER lists 2 projects funded under RFA-AI-24-010 in fiscal 2025 to 2026, at 2 institutions. The most were at University of California, San Francisco, Rutgers Biomedical and Health Sciences.

### Who has won Allergy and Infectious Diseases Research grants before?

The largest recipients over five fiscal years were Fred Hutchinson Cancer Center, Duke University, University of California, Los Angeles. The program made 13,282 awards worth $22 billion in that time.